U.S. Markets closed

Kamada (KMDA) Gains As Market Dips: What You Should Know

Zacks Equity Research

Kamada (KMDA) closed at $5.83 in the latest trading session, marking a +1.57% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.75%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, lost 0.57%.

Heading into today, shares of the biopharmaceutical had gained 1.59% over the past month, outpacing the Medical sector's loss of 4.67% and lagging the S&P 500's gain of 4% in that time.

KMDA will be looking to display strength as it nears its next earnings release. On that day, KMDA is projected to report earnings of $0.05 per share, which would represent year-over-year growth of 66.67%. Our most recent consensus estimate is calling for quarterly revenue of $22.87 million, up 31.14% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $0.47 per share and revenue of $126.91 million, which would represent changes of -17.54% and +10.87%, respectively, from the prior year.

Investors might also notice recent changes to analyst estimates for KMDA. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. KMDA currently has a Zacks Rank of #2 (Buy).

Valuation is also important, so investors should note that KMDA has a Forward P/E ratio of 12.3 right now. This valuation marks a discount compared to its industry's average Forward P/E of 22.24.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 77, putting it in the top 31% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow KMDA in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Kamada Ltd. (KMDA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.